Definium's Phase 3 Study Readout for DT120 ODT in MDD Sparks Investor Interest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Key Clinical Milestone: Definium Therapeutics' Emerge study is one of two pivotal Phase 3 trials evaluating the efficacy of DT120 ODT in adults with major depressive disorder (MDD), with results from 149 participants poised to be a significant catalyst for the company's future growth.
- Dosage and Efficacy: The trial tests whether a single 100-microgram dose of DT120 ODT can significantly reduce depressive symptoms, with the primary endpoint being the change in Montgomery-Åsberg Depression Rating Scale scores at Week 6, and positive results could drive the company's stock price higher.
- Positive Market Reaction: Ahead of the anticipated topline results from the Emerge study, Definium's shares surged nearly 12% in pre-market trading on Monday, reflecting strong investor confidence and market anticipation surrounding the drug's potential.
- Investor Sentiment Surge: Data from Stocktwits indicates that sentiment around Definium's stock is trending in the 'extremely bullish' territory, with an 83% year-to-date increase and a 245% rise over the past 12 months, showcasing optimistic expectations for its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DFTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DFTX
Wall Street analysts forecast DFTX stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.430
Low
20.00
Averages
35.89
High
61.00
Current: 24.430
Low
20.00
Averages
35.89
High
61.00
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Definium's Phase 3 Study Readout for DT120 ODT in MDD Sparks Investor Interest
- Key Clinical Milestone: Definium Therapeutics' Emerge study is one of two pivotal Phase 3 trials evaluating the efficacy of DT120 ODT in adults with major depressive disorder (MDD), with results from 149 participants poised to be a significant catalyst for the company's future growth.
- Dosage and Efficacy: The trial tests whether a single 100-microgram dose of DT120 ODT can significantly reduce depressive symptoms, with the primary endpoint being the change in Montgomery-Åsberg Depression Rating Scale scores at Week 6, and positive results could drive the company's stock price higher.
- Positive Market Reaction: Ahead of the anticipated topline results from the Emerge study, Definium's shares surged nearly 12% in pre-market trading on Monday, reflecting strong investor confidence and market anticipation surrounding the drug's potential.
- Investor Sentiment Surge: Data from Stocktwits indicates that sentiment around Definium's stock is trending in the 'extremely bullish' territory, with an 83% year-to-date increase and a 245% rise over the past 12 months, showcasing optimistic expectations for its future performance.
See More
Trump's Executive Order Accelerates Psychedelic Drug Development
- Investor Capital Influx: Trump's executive order has sparked interest among investors in psychedelic drug development companies, with Enveric Biosciences raising $5 million following the announcement, indicating heightened market attention despite researchers cautioning that new treatments are still far from realization.
- Improved FDA-DEA Coordination: Nine executives and investors noted that the order could shorten administrative timelines and enhance coordination between the FDA and DEA, potentially saving clinical-stage companies tens of millions in costs and improving overall research efficiency.
- Reduced Regulatory Uncertainty: Sa'ad Shah, co-founder of Noetic Fund, highlighted that the executive order may attract institutional investors like sovereign wealth funds and public pension plans into the psychedelic sector, alleviating previous regulatory uncertainties and signaling credible government backing for the industry.
- Accelerated Development Processes: Robert Barrow, CEO of Definium Therapeutics, stated that the implementation of the order will streamline regulatory processes, particularly allowing the DEA to begin scheduling controlled substances after FDA approval, which will facilitate faster market access for psychedelic drugs.
See More
Mind Medicine Reports Q1 Loss with Increased R&D Spending
- Earnings Loss: Mind Medicine reported a GAAP EPS of -$0.71 for Q1 2026, missing estimates by $0.21, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, Definium Therapeutics had cash, cash equivalents, and investments totaling $373.4 million, down from $411.6 million as of December 31, 2025, reflecting tightening liquidity.
- Increased R&D Spending: R&D expenses rose to $41.5 million in Q1 2026 from $23.4 million in Q1 2025, an increase of $18.1 million primarily due to higher costs in the DT120 ODT program and expanded personnel, highlighting ongoing investment in research.
- Sufficient Funding Outlook: Despite the cash decline, the company believes its current resources will fund operations into 2028, indicating management's confidence in future growth despite short-term financial pressures.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
White House Psychedelics Executive Order Accelerates Research
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Definium's Phase 3 Study Readout for DT120 ODT in MDD Sparks Investor Interest
- Key Clinical Milestone: Definium Therapeutics' Emerge study is one of two pivotal Phase 3 trials evaluating the efficacy of DT120 ODT in adults with major depressive disorder (MDD), with results from 149 participants poised to be a significant catalyst for the company's future growth.
- Dosage and Efficacy: The trial tests whether a single 100-microgram dose of DT120 ODT can significantly reduce depressive symptoms, with the primary endpoint being the change in Montgomery-Åsberg Depression Rating Scale scores at Week 6, and positive results could drive the company's stock price higher.
- Positive Market Reaction: Ahead of the anticipated topline results from the Emerge study, Definium's shares surged nearly 12% in pre-market trading on Monday, reflecting strong investor confidence and market anticipation surrounding the drug's potential.
- Investor Sentiment Surge: Data from Stocktwits indicates that sentiment around Definium's stock is trending in the 'extremely bullish' territory, with an 83% year-to-date increase and a 245% rise over the past 12 months, showcasing optimistic expectations for its future performance.
See More
Trump's Executive Order Accelerates Psychedelic Drug Development
- Investor Capital Influx: Trump's executive order has sparked interest among investors in psychedelic drug development companies, with Enveric Biosciences raising $5 million following the announcement, indicating heightened market attention despite researchers cautioning that new treatments are still far from realization.
- Improved FDA-DEA Coordination: Nine executives and investors noted that the order could shorten administrative timelines and enhance coordination between the FDA and DEA, potentially saving clinical-stage companies tens of millions in costs and improving overall research efficiency.
- Reduced Regulatory Uncertainty: Sa'ad Shah, co-founder of Noetic Fund, highlighted that the executive order may attract institutional investors like sovereign wealth funds and public pension plans into the psychedelic sector, alleviating previous regulatory uncertainties and signaling credible government backing for the industry.
- Accelerated Development Processes: Robert Barrow, CEO of Definium Therapeutics, stated that the implementation of the order will streamline regulatory processes, particularly allowing the DEA to begin scheduling controlled substances after FDA approval, which will facilitate faster market access for psychedelic drugs.
See More
Mind Medicine Reports Q1 Loss with Increased R&D Spending
- Earnings Loss: Mind Medicine reported a GAAP EPS of -$0.71 for Q1 2026, missing estimates by $0.21, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, Definium Therapeutics had cash, cash equivalents, and investments totaling $373.4 million, down from $411.6 million as of December 31, 2025, reflecting tightening liquidity.
- Increased R&D Spending: R&D expenses rose to $41.5 million in Q1 2026 from $23.4 million in Q1 2025, an increase of $18.1 million primarily due to higher costs in the DT120 ODT program and expanded personnel, highlighting ongoing investment in research.
- Sufficient Funding Outlook: Despite the cash decline, the company believes its current resources will fund operations into 2028, indicating management's confidence in future growth despite short-term financial pressures.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
- Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
- Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
- Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.
See More
White House Psychedelics Executive Order Accelerates Research
- Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
- Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
- Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
- Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
